Literature DB >> 16634126

The impact of diagnosis and plaque radiotherapy treatment of malignant choroidal melanoma on patients' quality of life.

Jens Reimer1, Anja Voigtlaender-Fleiss, Anne Karow, Norbert Bornfeld, Joachim Esser, Gabriele Helga Franke.   

Abstract

Quality of life (QOL) has become an important outcome criterion of medical interventions, but the impact of diagnosis and radiotherapy on QOL in patients with malignant choroidal melanoma (MCM) has rarely been studied. Inventories covering global (SF-36) and disease-specific QOL (NEI-VFQ), mental distress (SCL-90-R), and social support (K-22, German) were applied to a consecutive sample of MCM-patients scheduled for plaque radiotherapy. Data were gathered preoperatively (t(0)) and 3 months postoperatively (t(1), except for the K-22, which was applied at t(0) only). Fifty-four patients took part in both surveys, the number of patients with visual impairment increased from 21 preoperatively to 34 postoperatively. Global QOL of MCM-patients was significantly reduced compared to the healthy norm and other ophthalmological patients both at t(0) and t(1). Clinically relevant distress was present in every second patient at t(0) and every third patient at t(1), social support was not impaired. Global and disease-specific QOL declined significantly from t(1) to t(0). The MCM diagnosis compromises QOL, which is additionally impaired by radiotherapy. Regular QOL assessment can help to identify patients at risk, facilitate provision of psychosocial treatment and may thus improve patient satisfaction. Copyright 2006 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2006        PMID: 16634126     DOI: 10.1002/pon.1046

Source DB:  PubMed          Journal:  Psychooncology        ISSN: 1057-9249            Impact factor:   3.894


  8 in total

1.  Two-year patient-reported outcomes following treatment of uveal melanoma.

Authors:  L Hope-Stone; S L Brown; H Heimann; B Damato; P Salmon
Journal:  Eye (Lond)       Date:  2016-09-02       Impact factor: 3.775

2.  [Quality of life - methodology and clinical practice aspects with a focus on ocular medicine].

Authors:  G H Franke; C Gall
Journal:  Ophthalmologe       Date:  2008-08       Impact factor: 1.059

3.  Quality of life and cancer-related needs in patients with choroidal melanoma.

Authors:  Joshua F Wiley; Kelsey Laird; Tammy Beran; Tara A McCannel; Annette L Stanton
Journal:  Br J Ophthalmol       Date:  2013-09-13       Impact factor: 4.638

4.  Quality of Life Concerns in Patients with Uveal Melanoma after Initial Diagnosis.

Authors:  Christopher A Barker; Anna Kozlova; Alexander N Shoushtari; Jennifer L Hay; Jasmine H Francis; David H Abramson
Journal:  Ocul Oncol Pathol       Date:  2019-09-27

Review 5.  Psychological distress is associated with vision-related but not with generic quality of life in patients with visual field defects after cerebral lesions.

Authors:  Carolin Gall; Iris Mueller; Gabriele H Franke; Bernhard A Sabel
Journal:  Ment Illn       Date:  2012-09-06

Review 6.  Quality of Life, Depression, and Anxiety in Patients with Uveal Melanoma: A Review.

Authors:  Mario Miniati; Maria Grazia Fabrini; Federica Genovesi Ebert; Maricia Mancino; Alessandra Maglio; Gabriele Massimetti; Enrico Massimetti; Donatella Marazziti
Journal:  J Oncol       Date:  2018-03-20       Impact factor: 4.375

7.  Psychosocial impact of prognostic genetic testing in uveal melanoma patients: a controlled prospective clinical observational study.

Authors:  Marietta Lieb; Sefik Tagay; Anja Breidenstein; Tobias Hepp; Claudia H D Le Guin; Jennifer Scheel; Dietmar R Lohmann; Norbert Bornfeld; Martin Teufel; Yesim Erim
Journal:  BMC Psychol       Date:  2020-01-31

8.  Psychosocial impact of prognostic genetic testing in the care of uveal melanoma patients: protocol of a controlled prospective clinical observational study.

Authors:  Yesim Erim; Jennifer Scheel; Anja Breidenstein; Claudia Hd Metz; Dietmar Lohmann; Hans-Christoph Friederich; Sefik Tagay
Journal:  BMC Cancer       Date:  2016-07-07       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.